Tokyo’s Takeda Pharmaceutical (TSE: 4502) is progressing its Zika vaccine candidate TAK-426 into Phase I trials, backed by funding from the US Department of Health and Human Services (HSS), the company has announced.
A trial involving 240 male and female subjects in the USA between the ages of 18 and 49 will assess the safety and immunogenicity at several dose levels.
Both Takeda and French drugmaker Sanofi (Euronext: SAN) have been developing Zika vaccines using inactivated forms of the virus.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze